7th Anniversary Q&A 5: How to Break Global Regulatory Barriers and Achieve One Single Study for Multi‑Country IND Filings?

Preclinical CRO

Chinese innovative drugs are moving quickly toward globally synchronized development, multi-country IND filings, and out‑licensing. But regulatory standards diverge, GLP requirements, animal welfare rules, and data formats differ significantly across markets: leaving companies in a bind: repeat the studies and pay in cost and time, or reuse existing data and risk deficiency letters, or outright […]

7th Anniversary Q&A 4: From Isolated Capabilities to a Symbiotic Ecosystem — How Is Medicilon Building a New Drug Innovation Ecosystem?

Preclinical CRO

How can new drug candidates clear R&D hurdles and advance from lab concepts to clinical trials? Seven years after its STAR Market listing, Medicilon delivers a CRO answer: stepping beyond isolated service nodes to build an open, evolving innovation ecosystem that unites original research, translational maturation, capital support, AI enablement, talent development and client collaboration. […]

Search Medicilon

Preclinical CRO

China’s First mRNA-Based In Vivo CAR-T Candidate! Medicilon Supports Regenelead RGL-208 IND Approval

Preclinical CRO

Medicilon and China Pharmaceutical University Forge Industry-University Research Collaboration on Novel Conjugate Therapeutics to Empower New Drug Innovation

Preclinical CRO

7th Anniversary Q&A 7: Seven Years Listed, Honors Without Number: Why Does Medicilon Keep the Trust of the Industry and Its Clients?

Contact Medicilon

Name(Required)
Address(Required)